- Home
- SNY vs ITRM Comparison
SNY vs ITRM Comparison
Compare SNY & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- ITRM
- Stock Information
- Founded
- SNY 1994
- ITRM 2015
- Country
- SNY France
- ITRM Ireland
- Employees
- SNY N/A
- ITRM N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- SNY Health Care
- ITRM Health Care
- Exchange
- SNY Nasdaq
- ITRM Nasdaq
- Market Cap
- SNY 113.4B
- ITRM 40.0M
- IPO Year
- SNY N/A
- ITRM 2018
- Fundamental
- Price
- SNY $46.97
- ITRM $0.67
- Analyst Decision
- SNY Buy
- ITRM Strong Buy
- Analyst Count
- SNY 4
- ITRM 1
- Target Price
- SNY $61.50
- ITRM $9.00
- AVG Volume (30 Days)
- SNY 2.7M
- ITRM 682.8K
- Earning Date
- SNY 10-24-2025
- ITRM 11-13-2025
- Dividend Yield
- SNY 3.40%
- ITRM N/A
- EPS Growth
- SNY 118.56
- ITRM N/A
- EPS
- SNY 8.65
- ITRM N/A
- Revenue
- SNY $53,714,621,258.00
- ITRM N/A
- Revenue This Year
- SNY $1.53
- ITRM N/A
- Revenue Next Year
- SNY $7.06
- ITRM $482.25
- P/E Ratio
- SNY $5.43
- ITRM N/A
- Revenue Growth
- SNY 15.65
- ITRM N/A
- 52 Week Low
- SNY $44.73
- ITRM $0.61
- 52 Week High
- SNY $60.12
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- SNY 43.02
- ITRM 41.36
- Support Level
- SNY $46.50
- ITRM $0.66
- Resistance Level
- SNY $47.69
- ITRM $0.76
- Average True Range (ATR)
- SNY 0.68
- ITRM 0.05
- MACD
- SNY -0.18
- ITRM 0.01
- Stochastic Oscillator
- SNY 36.14
- ITRM 41.04
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.